Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2013-001347-31 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Nuvisan | UNKNOWN |
| Datamap | INDUSTRY |
| ClinIntel | INDUSTRY |
| Catalent |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
maldigestion of dietary macronutrients (pancreas not producing enough enzymes for digestion of fat, sugars and proteins) in diabetes type II
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Creon | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Creon | Drug | Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Recovery rate of 13CO2 (carbon dioxide with stable isotope of carbon) | from baseline up to the week 12 visit |
| Measure | Description | Time Frame |
|---|---|---|
| Change in nutritional parameters | fat soluble vitamins (D and E), retinol-binding protein, albumin, pre-albumin, magesium and calcium will be measured. | from baseline up to the week 12 visit |
| Change in HbA1c |
| Measure | Description | Time Frame |
|---|---|---|
| vital signs | blood pressure and heart rate, body weight and BMI | from baseline up to the week 12 visit |
| routine safety laboratory | Hematology, biochemistry and a urine pregnancy test will be performed |
Inclusion Criteria:
Inclusion Criterion at Visit 1:
• FE-1 (fecal elastase 1) <100μg/g of stool
Inclusion Criterion at Visit 2:
• 13C MTBT of <29% 13CO2-CRR (Carbon dioxide-Cumulative Recovery Rate)
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Suntje Sander-Struckmeier, PhD | Abbott | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site reference no. 113456 | Bochum | 44789 | Germany | |||
| Site reference no. 113477 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Creon 25000 matching Placebo | Drug | Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks |
|
| from baseline up to the week 12 visit |
| Change in quality of life assessed via a questionnaire Gastrointestinal-Quality of Life Index (GIQL) | from baseline up to the week 12 visit |
| Change in clinical global impression of disease symptoms | disease symptoms will be rated by the subject according a rating scale | from baseline up to the week 12 visit |
| from baseline up to the week 12 visit |
| Frankfurt |
| 60594 |
| Germany |
| Site reference no. 113476 | Pohlheim | 35415 | Germany |
| Site reference no. 113475 | Ulm | 89073 | Germany |
| Site reference no. 112517 | Ávila | 05004 | Spain |
| Site reference no. 112519 | Madrid | 28034 | Spain |
| Site reference no. 112520 | Málaga | 29071 | Spain |
| Site reference no. 112495 | Santiago de Compostela | 15706 | Spain |
| Site reference no. 112518 | Segovia | 40002 | Spain |
| Site reference no. 112496 | Seville | 41014 | Spain |
| ID | Term |
|---|---|
| D010188 | Exocrine Pancreatic Insufficiency |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020799 | Pancrelipase |
| ID | Term |
|---|---|
| D008049 | Lipase |
| D002265 | Carboxylic Ester Hydrolases |
| D004950 | Esterases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D010184 | Pancreatic Extracts |
| D014020 | Tissue Extracts |
| D045424 | Complex Mixtures |
Not provided
Not provided